4D Molecular Therapeutics (FDMT) just unveiled an announcement.
4D Molecular Therapeutics, Inc. is set to unveil interim data from its PRISM clinical trial for 4D-150, a treatment for wet age-related macular degeneration, at a medical conference in September 2024. Details on the presentation will align with the company’s second-quarter financial report in August 2024. The 52-week analyses for the trial’s cohorts are on track for release in February 2025.
For detailed information about FDMT stock, go to TipRanks’ Stock Analysis page.
